Trial Profile
A Phase I Dose Escalation Study of MK2461 in Patients With Advanced Cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs MK 2461 (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Merck & Co
- 08 Jan 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
- 08 Jan 2009 Actual start date (Feb 2007) added as reported by ClinicalTrials.gov.
- 17 Dec 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.